Risks of suicidality in adult patients with epilepsy

Table 1 Demographic and clinical features of the studied group of epilepsy (mean ± SD) n (%)

Demographic and clinical features	Patients (n = 200)	Patients with history of suicidality (n = 70)	Patients without history of suicidality (n = 130)
Male/female	100/100	34/36	66/64
Age (yr)	20-48 (30.47 ± 7.56)	20-48 (29.33 ± 7.60)	20-48 (31.08 ± 7.50)
Age at onset of disease (yr)	1-40 (16.24 ± 8.40)	1-39 (15.46 ± 8.66)	1-40 (16.66 ± 8.26)
Duration of illness (yr)	3-35 (13.94 ± 7.24)	3-31 (13.77 ± 6.93)	3-35 (14.04 ± 7.42)
Type of epilepsy
GTC	76 (38.0)	23 (32.9)	53 (40.8)
Complex partial/partial epilepsy with secondary generalization	124 (62.0)	47 (67.1)	77 (59.2)
Frontal	60 (48.39)	22 (46.81)	38 (49.35)
Temporal	58 (46.77)	23 (48.94)	35 (45.45)
Parietal	5 (4.03)	1 (2.13)	4 (5.19)
Occipital	1 (0.80)	1 (2.13)	0
Side of epileptic activity
Right	50 (40.32)	22 (46.81)	28 (36.36)
Left	74 (59.68)	25 (53.19)	49 (63.63)
AED(s) utilized
CBZ	114 (57.0)	31 (44.3)	83 (63.8)
VPA	48 (24.0)	21 (30.0)	27 (20.8)
Polytherapy	38 (19.0)	18 (25.7)	20 (15.4)
Dose of AED(s) (mg/d)
CBZ	400-1200 (750.54 ± 350.5)	400-1200 (700.24 ± 320.25)	400-1200 (760.25 ± 300.25)
VPA	200-1400 (850.50 ± 345.7)	200-1400 (840.30 ± 305.75)	200-1400 (730.50 ± 255.7)
Duration of treatment (yr)	2-30 (9.28 ± 4.02)	2-30 (9.28 ± 4.02)	2-30 (9.38 ± 4.39)
Serum drug level (μg/mL)
CBZ	4.30-12.80 (9.56 ± 4.5)	4.30-12.80 (9.56 ± 4.5)	4.30-12.80 (9.56 ± 4.5)
VPA	35.54-120.45 (80.50 ± 30.0)	35.54-120.4 (100.50 ± 30.0)	35.54-120.4 (85.50 ± 25.0)
Degree of control on AED(s)
Controlled	45 (22.5)	9 (12.9)	24 (26.2)
Partially controlled	47 (23.5)	14 (20.0)	3 (25.4)
Uncontrolled	108 (54.0)	47 (67.1)	63 (48.5)

GTC: Generalized tonic-clonic; AEDs: Antiepileptic drugs; CBZ: Carbamazepine; VPA: Valproate; Controlled: Seizure free for ≥ 1 year; Partially controlled: Occasional or rare in frequency; Uncontrolled: Very frequent or frequent in frequency.